

MusclePharm Corp  
Form 8-K  
September 22, 2011

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF  
THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): September 16, 2011

MusclePharm Corporation  
(Exact name of registrant as specified in its charter)

|                                                             |                                    |                                                          |
|-------------------------------------------------------------|------------------------------------|----------------------------------------------------------|
| Nevada<br>(State or other jurisdiction<br>of incorporation) | 000-53166<br>(Commission File No.) | 77-0664193<br>(I.R.S. Employer<br>Identification Number) |
|-------------------------------------------------------------|------------------------------------|----------------------------------------------------------|

4721 Ironton Street, Building A  
Denver, Colorado 90839  
(Address of principal executive offices)

(303) 396-6100  
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Resignation of Executive Vice President

On September 16, 2011, Leonard K. Armenta resigned from his position as the Executive Vice President of MusclePharm Corporation, a Nevada corporation (the "Company"). His resignation was not the result of any disagreements with the Company on any matters relating to the Company's operations, policies or practices.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

MUSCLEPHARM CORPORATION

Date: September 22, 2011

By: /s/ Brad J. Pyatt  
Name: Brad J. Pyatt  
Title: Chief Executive Officer